Novel drug delivery systems: Desired feat for tuberculosis

Journal of Advanced Pharmaceutical Technology and Research

Volumn 1, Issue 2, 2010, Pages 145-163

  Kaur, Kirtipal ^a   Gupta, Anuj ^a   Narang, R K ^a   Murthy, R S R ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Mycobacterium tuberculosis; Novel drug delivery system; Therapy; Tuberculosis

Indexed keywords

ALPHA TOCOPHEROL; AMIKACIN; AMINOSALICYLIC ACID; ASCORBIC ACID; BCG VACCINE; BETA CAROTENE; CAPREOMYCIN; CYCLOSERINE; DRUG CARRIER; ESSENTIAL FATTY ACID; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; HERBACEOUS AGENT; ISONIAZID; KANAMYCIN A; LEVOFLOXACIN; MOXIFLOXACIN; MULTIVITAMIN; PYRAZINAMIDE; RETINOL; RIFABUTIN; RIFAMPICIN; RIFAMYCIN DERIVATIVE; STREPTOMYCIN; THIOSEMICARBAZONE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VITAMIN B COMPLEX; ZINC;

ABDOMINAL PAIN; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BLEEDING; BLURRED VISION; CELL LEVEL; CYTOSOL; DIET THERAPY; DISEASE COURSE; DIZZINESS; DRUG CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FEVER; GENE EXPRESSION; HEARING LOSS; HOST PATHOGEN INTERACTION; HUMAN; INFECTION SENSITIVITY; MICROBIAL ACTIVITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OTOTOXICITY; PARESTHESIA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN BRUISING; SKIN DISCOLORATION; TUBERCULOSIS; TUBERCULOSIS CONTROL; VISION;

EID: 79952998727     PISSN: 22314040     EISSN: 09762094     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Daniel T. M. The history of tubercular. Respiratory Medicine. 2006; 100:1862-1870.
2. Kusner D.J. Mechanisms of mycobacterial persistence in tuberculosis. Clinical munology. 2005; 14:239-247. (Pubitemid 40255129)
3. Rooijen NV., Sanders A.. The macrophage as target or obstacle in liposome-based targeting strategies. Int. J. Pharm. 1998; 162: 45-50. (Pubitemid 28166089)
4. Cotran, R.S., Kumar, V., Collins, T. Robbins:Pathologic Basis of Diseases, 6th ed. Saunder; 1999.
5. Aderem A., Underhill D.M.. Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol. 1999; 17:593-623. (Pubitemid 29241135)
6. Clemens D.L., Horwitz M. Characterization of the Mycobacterium tuberculosis phagosome and evidence that phagosomal maturation is inhibited. J. Exp. Med. 1995; 181:257-270.
7. Clemens D.L., Lee BY., Horwitz M.A. Deviant expression of Rab5 on phagosomes containing the intracellular pathogens Mycobacterium tuberculosis and Legionella pneumophila is associated with altered phagosomal fate. Infect. Immun. 2000; 68:2671-2684. (Pubitemid 30253841)
8. Sturgill-Koszycki, S., Schlesinger P.H., Chakraborty P., Haddix P.L., Collins H.L., Fof A.K., Allen R.D., Gluck S.L., Heuser J., Russel D.G.. Lack of acidification in mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science. 1994; 263:678-68.
9. Ferrari G., Langen H., Natio M., Dieters J. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell. 1999; 97:435-447. (Pubitemid 29231167)
10. Kinger A.K., Tyagi J.S. Identification and cloning of genes differentially expressed in the virulent strain of M. tuberculosis. Gene. 1993; 131:113-117.
11. Tobe T., Nagai S. Temperature-regulated invasion gene in Shigella flexneri controlled through the transcriptional activation of the virB gene on the large plasmid. Mol. Microbiol. 1991; 5: 887-893. (Pubitemid 21896112)
12. Cornelis G., Sluiters C. Homology between VirP, the transcriptional activator of the Yersinia virulence regulon and AraC, the E. coli arabinose operon regulator. J. Bacteriol. 1989; 171: 254-262. (Pubitemid 19031404)
13. Brunton, L.L., Slazo, J., Parker, K. L.. Goodman and Gilmans.The pharmacological basis of therapeutics. 11th ed. McGrawHill; 2006.
14. Martin G.P., Zeng X.M., Marriott C. The controlled delivery of drugs to the lungs. Int. J. Pharm.1995; 124:149-164.
15. Bryon P.R. Prediction ofdrug residence time, in region of the human respiratory tract following aerosol inhalation. J.Pharm. Sci. 1986; 75:433-438.
16. Hoet P.H., Bruske-Hohlfeld I., Salata O. V. Nanoparticles-known and unknown health risks. J. Nanobiotechnol. 2004; 2: 12.
17. Stone K.C., Mercer ER., Gehr P., Stockstill B., Capro J. D.. Allometric relationships of cell numbers and size in the mammalian lung. Am. J. Respir. Cell Mol. Biol. 1992; 6:235-243.
18. Gehr P. The normal human lung: ultrastructure and morphometric estimations of diffusion capacity. Physiol. 1978; 32:121-140. (Pubitemid 8295531)
19. Courrier H.M., Butz N., Vandamme T.P. Pulmonary drug delivery systems: recent developments and prospects. Crit. Rev. Ther. Drug Carrier Syst. 2002; 19:425-498. (Pubitemid 36314479)
20. Gref R., Domb A., Quellec P. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug. Deliv. Rev. 1995; 16:215.
21. Couvier C., Millot J. Doxorubicin loaded nanospheres bypass tumor cell multidrug resistance. Biochem. Pharmacol. 1992; 44:509-517.
22. Kellaway I.W., Parr S.J. Liposomes as drug delivery systems to the lungs. Adv. Drug Del. Rev. 1990; 5:149-161. (Pubitemid 20333021)
23. Couvreur P., Pattal E., Andremont A. Liposomes and nanoparticles in the treatment of intracellular bacterial infections. Pharm. Res. 1991; 8:1079-1086.
24. Schreier H., McNicol K.J. Pulmonary delivery of amikacin lposomes and acute liposome toxicity in the sheep. Int. J. Pharm. 1992; 87:183-193.
25. Pandey R., Sharma S., Khuller G.K. Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. International Journal of Antimicrobial Agents. 2004; 24:93-94. (Pubitemid 38844571)
26. Vyas S.P., Kannan M.E., Jamn S.. Design of liposomal aerosol for improved delivery of rifampicin to alveolar macrophages. Int. J. Pharm. 2004; 269:37-49. (Pubitemid 38035210)
27. Wichert By., Rothi R.J.G., Schreier H., Wichert B.M.. Amikacin liposomes: Characterization, aerosolization, and in vitro activity against Mycobacterium avium-intracellulare in alveolar macrophages. Int. J. Pharm. 1991; 78:227-235.
28. Antimisiaris SG, Mourtas S. Liposome for drug delivery to the lungs by nebulization. Eur. J. Pharm.& Biopharm. 2007; 67:655-666. (Pubitemid 47576612)
29. Antimisiaris S.G., Zaru M., Manca M.L. Colloids and surfaces B: Biointerfaces. 2009; 71:88-95.
30. Suarez S., O'Hara P., Kazantseva M.. Respirable PLGA microspheres containing rifampicin for the treatment oftuberculosis: screening in an infectious disease model. Pharm. Res. 2001; 18: 1315-1319. (Pubitemid 32846326)
31. Sharma R., Saxena D., Dwivedi A.K., Misra A. Inhaable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res. 2001; 18:1405-1410. (Pubitemid 32977245)
32. Tsapis N., Bennett D., O'Driscoll K. Direct lung delivery of para aminosalicylic acid by aerosol particles. Journal of Tuberculosis. 2003; 83:379-385. (Pubitemid 37464043)
33. Roverchon E., Marco I. D., Porta G. D. Rifampicin microparticle production by supercritical antisolvent precipitation. Int. J. Pharm. 2002; 243:83-91.
34. Pandey R., Sharma A., Zahoor A., Sharma S., Khuller GK., Prasad B.. Poly (DL-lactide-co glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother. 2003; 52:981-986. (Pubitemid 38008419)
35. Sharma A., Sharma S., Khuller G.K. Lectinfunctionalized poly (lactide-co-glycolide) nanoparticle as oral/ aerosolised antitubercular drug carriers for treatment of tuberculosis. J. Antimicrob. Chemother. 2004; 54:761-766. (Pubitemid 39386728)
36. Pandey R., Khuller G.K. Solid lipid nanoparticle based inhalable sustained drug delivery system against experimental tuberculosis. Journal of Tuberculosis. 2005; 85:227-234. (Pubitemid 40805619)
37. Giovagnoli S., Blasi P., Schoubben A., Rossi C., Ricci M.. Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery. Int. J. Pharm. 2007; 333:103-111. (Pubitemid 46283276)
38. Lasic, D.D. On the thermodynamic stability of liposomes. J. Clloid Interface Sci. 1990; 140: 302-304.
39. Uchegbu IF., Vyas S.P.. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int. J. Pharm. 1998; 172:33-70. (Pubitemid 28430243)
40. Illum L., Davis S., Muller, R.H. The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a blockpolymer-poloxasnine 908. Life Sci. 1986; 40:367-374.
41. Hertault B., Saulnier P., Pech B., Proust J.E., Benoit J.P.. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm. Res. 2002; 19:875-880. (Pubitemid 34692585)
42. Suarez S., O'Hara P., Kazantseva M. Airways delivery of rifarnpicin microparticles for the treatment of tuberculosis. Journal of Antimicrobial Chemotherapy. 2001; 48:431-434. (Pubitemid 32898818)
43. Barrow E.L., Winchester G.A, Staas J.K., Quenelle D.C., Barrow W.W. Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob. Agents Chemother. 1998; 42:2682-2689. (Pubitemid 28462915)
44. O'Hara P., Hickey A.J. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res. 2000; 17:955-961.
45. Dutt M., Khuller G.K. Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Int. J Antimicrob Agents. 2001; 17:115-122. (Pubitemid 32101566)
46. Kailasam S., Daneluzzi D., Gangadharam P.R.J. Maintenance of therapeutically active levels of isoniazid for prolonged periods in rabbits after a single implant of biodegradable polymer. Tuber. Lung Dis. 1994; 75(5):361-365. (Pubitemid 24336533)
47. Zahoor A., Sharma S., Khuller G.K. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int. J. Antimicrob. Agents. 2005; 26 (4) : 298-303. (Pubitemid 41338657)
48. Zahoor A., Pandey R., Sharma S., Khuller G.K. Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses. Int. J. Antimicrob. Agents, 2006; 27(5):409-416.
49. Ain Q., Sharma S., Garg S.K., Khuller G.K. Role of poly [DL-lactideco-glycolide] in development of a sustained oral delivery system for antitubercular drug(s). Int. J. Pharm. 2002; 239(1-2):37-46. (Pubitemid 34615793)
50. Prabakaran D., Singh P., Jaganathan K. S., Vyas S. P. Osmotically regulated asymmetric capsular systems for simultaneous sustained delivery of anti-tubercular drugs. J. Contr. Rel. 2004; 95(2) 239-248. (Pubitemid 38232673)
51. Dutt M., Khuller G. K. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles. J. Antimicrob. Chemother. 2001; 47(6):829-35. (Pubitemid 32519831)
52. Gangadharam P.R., Geeta N., Hsu Y.Y., Wise D.L. Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide. Int. J. Tuberc. Lung Dis. 1999; 3:515-520. (Pubitemid 29260165)
53. Comstock G.W. The age of selection of mortality from tuberculosis in successive decades. Am. J. Epidemiol. 1995; 141:790.
54. Nagelkerke N.J.D., Vlas S.J., MahendradhataY., Ottenhoff T.H.M., Borgdorff M.. The search for a tuberculosis vaccine: An elusive quest? Journal of tuberculosis. 2006; 86: 41-46. (Pubitemid 41799602)
55. Cole S.T., Heym B. Multidrug resistance in Mycobacterium tuberculosis. Int. J. Antimic. Agents. 1996; 8:61-70. (Pubitemid 27181887)